Abstract: A brake cylinder configured to provide braking signaling to an automotive simulator, the brake cylinder includes a damper housing, a resilient damper arranged within the damper housing and a piston configured to move a block in the axial direction at least partially into the damper housing towards said resilient damper. The block comprises a mechanical stop configured to limit the axial movement of the piston in the axial direction. The brake cylinder further has a sensor configured to measure a response to movement of said piston and send a signal to a processor indicative of that movement. The brake cylinder is configured to be connected to a brake pedal. The mechanical stop divides the braking process into two phases a first phase where the pedal can be depressed and a second phase where the pedal cannot be pressed further due to the mechanical stop. In one variant the brake cylinder is a purely mechanical system with only the damper housing or in combination with a single cylinder chamber.

Abstract: A brake cylinder includes a brake cylinder housing having a master chamber, a slave chamber, and a wall disposed there between. The wall defines at least one opening configured to provide fluid communication between the master chamber and the slave chamber. The brake cylinder also includes a master piston configured to pressurize fluid in the master chamber when a brake pedal is pressed. The brake cylinder further includes a slave piston and a pressure sensor disposed in fluid communication with the slave chamber. The pressure sensor is configured to measure pressure in the slave chamber and send a signal to a processor indicating of movement of the brake pedal. When pressurizing fluid in the master chamber, the master piston is configured to drive fluid from the master chamber to the slave chamber via the at least one opening to increase pressure in the slave chamber.

Abstract: The present invention provides an immunological binding partner reactive with a C-terminal epitope of the C5 domain of the ?3 chain of collagen Type 6, and a method of immunoassay using the immunological binding partner for detecting and quantifying the C-terminal epitope. The invention also provides a method of investigating the rate of formation of extracellular matrix and a method for identifying a subject suitable for treatment with an insulin sensitizer.

Abstract: Disclosed herein are calcitonin mimetics that are acylated at a lysine residue located at the 11 position or 19 position of the calcitonin mimetic, and the use thereof as medicaments in the treatment of various diseases and disorders, including diabetes, excess bodyweight, excessive food consumption and metabolic syndrome, NASH, alcoholic and non-alcoholic fatty liver disease, the regulation of blood glucose levels, the regulation of response to glucose tolerance tests, the regulation of food intake, and the treatment of osteoporosis and the treatment of osteoarthritis.

Abstract: A brake cylinder for use with an automotive simulator includes a brake cylinder housing having a master chamber, a slave chamber, a wall disposed therebetween and at least one channel configured to provide fluid communication between the master chamber and the slave chamber. In some variants, the at least one channel may be an opening configured to provide fluid communication between the master chamber and the slave chamber, in another variant the channel may be an external channel such as a tube. The brake cylinder also includes a master piston configured to pressurize fluid in the master chamber when a brake pedal is pressed. The brake cylinder further includes a slave piston and a pressure sensor disposed in fluid communication with the brake cylinder. The pressure sensor is configured to measure pressure in the chambers and send a signal to a processor indicative of movement of the brake pedal.

Abstract: A brake cylinder includes a brake cylinder housing having a master chamber, a slave chamber, and a wall disposed there between. The wall defines at least one opening configured to provide fluid communication between the master chamber and the slave chamber. The brake cylinder also includes a master piston configured to pressurize fluid in the master chamber when a brake pedal is pressed. The brake cylinder further includes a slave piston and a pressure sensor disposed in fluid communication with the slave chamber. The pressure sensor is configured to measure pressure in the slave chamber and send a signal to a processor indicating of movement of the brake pedal. When pressurizing fluid in the master chamber, the master piston is configured to drive fluid from the master chamber to the slave chamber via the at least one opening to increase pressure in the slave chamber.

Abstract: A brake cylinder configured to provide braking signaling to an automotive simulator, the brake cylinder includes a damper housing, a resilient damper arranged within the damper housing and a piston configured to move a block in the axial direction at least partially into the damper housing towards said resilient damper. The block comprises a mechanical stop configured to limit the axial movement of the piston in the axial direction. The brake cylinder further has a sensor configured to measure a response to movement of said piston and send a signal to a processor indicative of that movement. The brake cylinder is configured to be connected to a brake pedal. The mechanical stop divides the braking process into two phases a first phase where the pedal can be depressed and a second phase where the pedal cannot be pressed further due to the mechanical stop. In one variant the brake cylinder is a purely mechanical system with only the damper housing or in combination with a single cylinder chamber.

Abstract: The present invention relates to humanised calcitonin mimetics and their use in treating diabetes (Type I and/or Type II), excess bodyweight, excessive food consumption, metabolic syndrome, rheumatoid arthritis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease, alcoholic fatty liver disease, osteoporosis, or osteoarthritis, poorly regulated blood glucose levels, poorly regulated response to glucose tolerance tests, or poor regulation of food intake.

Abstract: Calcitonin analogues as a medicament for producing a decrease in liver triglycerides or for reducing fat accumulation in the liver of a subject are provided.

Abstract: The present invention provides an immunological binding partner reactive with a C-terminal epitope of the C5 domain of the ?3 chain of collagen Type 6, and a method of immunoassay using the immunological binding partner for detecting and quantifying the C-terminal epitope. The invention also provides a method of investigating the rate of formation of extracellular matrix and a method for identifying a subject suitable for treatment with an insulin sensitizer.

Abstract: Calcitonin analogues as a medicament for producing a decrease in liver triglycerides or for reducing fat accumulation in the liver of a subject are provided.

Abstract: Calcitonin mimetic peptides having an amino acid sequence in accordance with SEQ ID NO:8 or SEQ ID NO:53, each of which may be carboxylated at its N-terminal or otherwise modified to reduce the positive charge of the first amino acid and independently of that may be amidated at its C-terminal, and in each of which the 1 and 7 position cysteine residues may together be replaced by ?-aminosuberic acid (Asu) are useful for methods of treating diabetes (Type I and/or Type II), obesity, excessive food consumption, metabolic syndrome, rheumatoid arthritis, non-alcoholic fatty liver disease, osteoporosis, or osteoarthritis, poorly regulated blood glucose levels, poorly regulated response to glucose tolerance tests, or poorly regulated food intake.

Abstract: Provided herein are methods for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. A peptide selected from sequences SEQ ID NO: 12, SEQ ID NO: 15 and SEQ ID NO: 17 are administered.

Abstract: Calcitonin mimetic peptides having an amino acid sequence in accordance with SEQ ID NO:8 or SEQ ID NO:53, each of which may be carboxylated at its N-terminal or otherwise modified to reduce the positive charge of the first amino acid and independently of that may be amidated at its C-terminal, and in each of which the 1 and 7 position cysteine residues may together be replaced by ?-aminosuberic acid (Asu) are useful as medicaments for treating diabetes (Type I and/or Type II), excess bodyweight, excessive food consumption, metabolic syndrome, rheumatoid arthritis, non-alcoholic fatty liver disease, osteoporosis, or osteoarthritis, poorly regulated blood glucose levels, poorly regulated response to glucose tolerance tests, or poorly regulated of food intake.

Abstract: Calcitonin analogues as a medicament for producing a decrease in liver triglycerides or for reducing fat accumulation in the liver of a subject are provided.

Abstract: A cooling module row for an inline-memory module is provided. The cooling module row may include an inlet chamber and an outlet chamber positioned at a same end of the cooling module row. The cooling module row may also include a conduit in fluid communication with the inlet chamber and the outlet chamber. The conduit may be sized to fit adjacent the in-line memory module. A method of heat management for an in-line memory module is also provided. The method may include positioning a cooling module row adjacent the in-line memory module, the cooling module row having an inlet chamber and an outlet chamber positioned at the same end of the cooling module row.

Abstract: Provided herein are methods for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. A peptide selected from sequences SEQ ID NO: 12, SEQ ID NO: 15 and SEQ ID NO: 17 are administered.

Abstract: The present invention provides an immunological binding partner reactive with a C-terminal epitope of the C5 domain of the ?3 chain of collagen Type 6, and a method of immunoassay using the immunological binding partner for detecting and quantifying the C-terminal epitope. The invention also provides a method of investigating the rate of formation of extracellular matrix and a method for identifying a subject suitable for treatment with an insulin sensitizer.

Abstract: Provided herein are peptides, that in combination with metformin, are effective for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. The peptides are selected from sequences SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24.

Abstract: A cooling module row for an inline-memory module is provided. The cooling module row may include an inlet chamber and an outlet chamber positioned at a same end of the cooling module row. The cooling module row may also include a conduit in fluid communication with the inlet chamber and the outlet chamber. The conduit may be sized to fit adjacent the in-line memory module. A method of heat management for an in-line memory module is also provided. The method may include positioning a cooling module row adjacent the in-line memory module, the cooling module row having an inlet chamber and an outlet chamber positioned at the same end of the cooling module row.